Clinical and experimental dermatology · 2014
Interleukin-33 affects cytokine production by keratinocytes in vitiligo.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li P, Ma H, Han D, Mou K
Аннотация
BACKGROUND: Vitiligo is an acquired skin pigmentation disorder. Interleukin (IL)-33 is a newly described member of the IL-1 family.
AIM: To examine the role of IL-33 and its regulation in vitiligo.
METHODS: Expression of IL-33 and its receptor (interleukin 1 receptor-like 1 protein; also known as ST2), in skin biopsies taken from healthy subjects and patients with vitiligo, was examined by immunofluorescence staining and western blotting. IL-33 secretion from primary keratinocytes was measured by ELISA. IL-33-stimulated release of stem cell factor (SCF), basic fibroblast growth factor (bFGF), IL-6 and tumour necrosis factor (TNF)-α from primary keratinocytes was examined by ELISA.
RESULTS: IL-33 and ST2 expression was increased in lesional skin, and serum IL-33 was raised in patients with vitiligo. IL-33 expression moved from the nucleus to the cytoplasm of keratinocytes. IL-33 reduced expression of both SCF and bFGF, but increased expression of both IL-6 and TNF-α expression in primary keratinocytes.
CONCLUSIONS: IL-33 is secreted by keratinocytes and functions as an alarmin. It may induce melanocyte death by regulating cytokines in the cellular microenvironment.
AIM: To examine the role of IL-33 and its regulation in vitiligo.
METHODS: Expression of IL-33 and its receptor (interleukin 1 receptor-like 1 protein; also known as ST2), in skin biopsies taken from healthy subjects and patients with vitiligo, was examined by immunofluorescence staining and western blotting. IL-33 secretion from primary keratinocytes was measured by ELISA. IL-33-stimulated release of stem cell factor (SCF), basic fibroblast growth factor (bFGF), IL-6 and tumour necrosis factor (TNF)-α from primary keratinocytes was examined by ELISA.
RESULTS: IL-33 and ST2 expression was increased in lesional skin, and serum IL-33 was raised in patients with vitiligo. IL-33 expression moved from the nucleus to the cytoplasm of keratinocytes. IL-33 reduced expression of both SCF and bFGF, but increased expression of both IL-6 and TNF-α expression in primary keratinocytes.
CONCLUSIONS: IL-33 is secreted by keratinocytes and functions as an alarmin. It may induce melanocyte death by regulating cytokines in the cellular microenvironment.